Hormonaly.ai
Evidence OS for modern medicine with 24 AI agents synthesizing clinical answers from PubMed studies.
Website: https://hormonaly.ai/
Cover Block
| Field | Value |
|---|---|
| Name | Hormonaly.ai |
| Tagline | Evidence OS for modern medicine with 24 AI agents synthesizing clinical answers from PubMed studies |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology Type | AI / Machine Learning |
| Founding Team | Fady Hannah-Shmouni, MD FRCPC |
Links
- Website: https://hormonaly.ai/
- Product (Copilot): https://hormonaly.ai/copilot
- Product (Lab): https://hormonaly.ai/lab
- Founder LinkedIn: https://www.linkedin.com/in/fady-hannah-shmouni/
- Instagram: https://www.instagram.com/hormonaly.ai/
- Founder X / Twitter: https://x.com/drshmouni
Executive Summary
Hormonaly.ai is positioning itself as a clinical-evidence operating system for peptide and hormone medicine. The company describes its product as a set of 24 specialized AI agents that synthesize answers from more than 10,000 PubMed studies, returning citations and protocols in under 100 milliseconds [Hormonaly.ai]. The founder, Dr. Fady Hannah-Shmouni, is an endocrinologist and geneticist whose public record includes a principal investigator role in the Stratakis Laboratory at the National Institutes of Health and a clinical professorship at the University of British Columbia [Erdheim-Chester Disease Foundation]. According to a LinkedIn post, the platform delivers 631 GRADE-rated protocols built for clinical workflows [LinkedIn].
Data Accuracy: YELLOW -- Founder credentials cross-confirmed across LinkedIn, the Erdheim-Chester Disease Foundation bio, and Yahoo Finance; product claims rely on the company's own surfaces.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Business Model | SaaS |
| Industry / Vertical | Healthtech, clinical decision support |
| Technology Type | AI / Machine Learning, agentic systems |
| Founding Team | Solo clinician founder of record |
How the Company Got Here
Hormonaly.ai presents itself as an "evidence OS for modern medicine" focused initially on peptide and hormone therapy [Hormonaly.ai]. The company's three public surfaces describe a platform that ingests randomized controlled trials, regulatory updates, and emerging compound data, then routes them through 24 agents tuned to clinical workflows [Hormonaly.ai].
The founder of record, Dr. Fady Hannah-Shmouni, is a board-certified endocrinologist whose biography includes service as associate program director of the NIH Inter-Institutes Endocrinology and Metabolism Fellowship, principal investigator on two NICHD protocols, and a current clinical professorship at the University of British Columbia [Erdheim-Chester Disease Foundation]. He was also recently named to the Medical Advisory Board of Science & Humans, a Canadian hormone-therapy clinic group [Yahoo Finance]. Public commentary from Hannah-Shmouni on podcasts including Mizter Rad, PHAMCAST, and Leaders On Purpose has centered on personalized medicine and the role of AI as a clinician-facing tool [Mizter Rad Show; PHAMCAST; Leaders On Purpose Podcast].
Data Accuracy: YELLOW -- Founder career history confirmed across two independent biographical sources; corporate formation details not publicly available.
Product and Technology
The product is described publicly as an AI operating system for peptide and hormone medicine, built around evidence-based protocols, real-time citations, and clinical-grade reasoning [Hormonaly.ai]. The marketing copy specifies a corpus of more than 10,000 PubMed studies and a response latency of under 100 milliseconds, with answers tagged using the GRADE framework [Hormonaly.ai]. A LinkedIn post attributed to the founder adds the figure of 631 GRADE-rated protocols delivered through the agent layer [LinkedIn].
The 24-agent architecture is the most distinctive design choice, with specialized agents mapped to clinical workflow steps [Hormonaly.ai]. The Copilot surface is positioned for use by healthcare providers at the point of care, and the Lab surface appears to be the protocol and evidence library [Hormonaly.ai].
Data Accuracy: ORANGE -- All product specifics derive from company-controlled surfaces; no independent technical review or customer reference has been located.
Market Research and Opportunity
The market is the clinical decision support for cash-pay longevity, hormone, and peptide medicine. Seed-stage capital in AI-adjacent verticals has continued to flow in 2025, with Crunchbase reporting that seed rounds in the $10 million to $50 million band grew roughly 20 percent year over year [Crunchbase, 2025].
| Metric | Value |
|---|---|
| PubMed studies in corpus | 10,000+ |
| GRADE-rated protocols delivered | 631 |
| Specialized AI agents | 24 |
| 2025 seed deals $10M-$50M, YoY growth | ~20% |
Data Accuracy: YELLOW -- Funding-environment data confirmed by Crunchbase; no third-party market-sizing report specific to the company's wedge is publicly available.
Competitive Landscape
Hormonaly enters a competitive field where no single player owns evidence-grade decision support for peptide and hormone medicine. Three categories are worth distinguishing: established clinical reference layers (UpToDate, DynaMed), generalist medical AI (OpenEvidence, Glass Health), and in-house protocol stacks built by vertically integrated hormone and longevity clinics [Yahoo Finance].
Where Hormonaly has a defensible edge today is founder-channel credibility. Hannah-Shmouni's NIH research record and UBC professorship give the product a clinical voice that a generalist medical-AI startup cannot easily replicate [Erdheim-Chester Disease Foundation; Hormonaly.ai].
Data Accuracy: ORANGE -- Competitor categories named from analyst knowledge of the space; no head-to-head comparison data has been published by Hormonaly or third parties.
Opportunity
If Hormonaly executes, the prize is to become the default evidence layer for a fast-growing slice of cash-pay medicine that the incumbent clinical reference tools have under-served.
Growth scenarios
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Clinic-chain reference customer | A named longevity or hormone clinic group adopts Hormonaly | Founder's advisory role at Science & Humans converts into a commercial pilot | Direct relationship already exists [Yahoo Finance] |
| Specialty-society endorsement | A hormone or anti-aging medicine society lists Hormonaly's protocols as a recommended reference | Publication of a peer-reviewed validation study | Founder has a peer-reviewed publication record at NIH [Erdheim-Chester Disease Foundation] |
| Vertical platform expansion | The 24-agent architecture extends into adjacent specialties | A second clinician co-founder or specialty lead joins | Agentic architectures are inherently extensible [Crunchbase, 2025] |
Data Accuracy: YELLOW -- Founder relationship to Science & Humans confirmed by Yahoo Finance; scenario sizing is explicitly labelled as analyst scenario rather than disclosed plan.
Sources
- [Hormonaly.ai] Hormonaly.ai - The Evidence OS | https://hormonaly.ai/
- [Hormonaly.ai] Hormonaly.ai - AI OS for Peptide & Hormone | https://hormonaly.ai/copilot
- [Hormonaly.ai] Hormonaly.ai - The Evidence OS (Lab) | https://hormonaly.ai/lab
- [LinkedIn] Fady Hannah-Shmouni, MD FRCPC - Hormonaly | https://www.linkedin.com/in/fady-hannah-shmouni/
- [LinkedIn] Hormonaly AI Platform for Evidence-Based Medicine | https://www.linkedin.com/posts/fady-hannah-shmouni_hormonaly-is-an-agentic-based-clinical-evidence-activity-7431945492172943360-O3Kk
- [LinkedIn] Hormonaly AI Clinical OS for Evidence-Based Peptide & Hormone | https://www.linkedin.com/posts/fady-hannah-shmouni_evidencebasedmedicine-peptides-hormonetherapy-activity-7421917834009776129-Hy19
- [LinkedIn] Hormonaly.ai - The Evidence OS (Philippe Gerwill post) | https://www.linkedin.com/posts/philippegerwill_hormonalyai-evidence-based-peptide-activity-7398246804150067200-KCky
- [Erdheim-Chester Disease Foundation] Fady Hannah-Shmouni, MD, DABIM, FRCPC - Webinar Bio | https://www.erdheim-chester.org/wp-content/uploads/2021/02/Hannah-Shmouni-Fady-Webinar-Bio.pdf
- [Loop Frontiers] Fady Hannah-Shmouni, MD FRCPC - Profile | https://loop.frontiersin.org/people/286065/overview
- [Yahoo Finance] Science & Humans Welcomes Dr. Fady Hannah-Shmouni to Medical Advisory Board | https://finance.yahoo.com/news/science-humans-h-welcomes-esteemed-225000426.html
- [Mizter Rad Show] Dr. Fady Hannah-Shmouni: Personalized Medicine and the Future of Aging | https://www.mizter-rad.com/episodes/44-aging-by-choice-dr-hannah-schmouni
- [PHAMCAST] Dr. Fady Hannah-Shmouni (Part 2) | https://podcasts.apple.com/ca/podcast/dr-fady-hannah-shmouni-part-2/id1700393383?i=1000665000074
- [PHAMCAST] Dr. Fady Hannah-Shmouni (Part 3) | https://open.spotify.com/episode/2UnZfmlKpc8BszIIVbE69u
- [Leaders On Purpose Podcast] Episode 47 - Dr. Fady Hannah-Shmouni: Be The CEO Of Your Health | https://open.spotify.com/episode/1wDp16c30HK04bG3J8up8E
- [X (Twitter)] Fady Hannah-Shmouni, MD FRCPC (@DrShmouni) | https://x.com/drshmouni
- [Crunchbase, 2025] Seed Funding Hasn't Stalled, But It's Skewing Larger | https://news.crunchbase.com/venture/seed-funding-skewing-larger-ai-competitive-data/
Articles about Hormonaly.ai
- Hormonaly.ai Wants Every Hormone Clinician Citing PubMed in Under 100 Milliseconds — Endocrinologist Fady Hannah-Shmouni is building 24 AI agents to deliver GRADE-rated protocols for peptide and hormone medicine.